A share price of Seres Therapeutics Inc [MCRB] is currently trading at $0.85, down -2.30%. An important factor to consider is whether the stock is rising or falling in short-term value. The MCRB shares have gain 2.29% over the last week, with a monthly amount glided 3.24%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Seres Therapeutics Inc [NASDAQ: MCRB] stock has seen the most recent analyst activity on October 24, 2024, when JP Morgan downgraded its rating to a Underweight. On April 21, 2023, JP Morgan initiated with a Neutral rating and assigned a price target of $7 on the stock. Goldman downgraded its rating to a Sell and decreased its price target to $7 on July 23, 2021. Chardan Capital Markets upgraded its rating to Buy for this stock on March 05, 2021, but kept the price target unchanged to $30. In a note dated September 18, 2020, Chardan Capital Markets downgraded an Neutral rating on this stock and revised its target price from $32.50 to $27.50.
Seres Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.54 and $2.05. Currently, Wall Street analysts expect the stock to reach $1.25 within the next 12 months. Seres Therapeutics Inc [NASDAQ: MCRB] shares were valued at $0.85 at the most recent close of the market. An investor can expect a potential return of 47.06% based on the average MCRB price forecast.
Analyzing the MCRB fundamentals
Trailing Twelve Months sales for Seres Therapeutics Inc [NASDAQ:MCRB] were 0.06M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at -108.88% with Operating Profit Margin at -2214.05%, Pretax Profit Margin comes in at -2582.59%, and Net Profit Margin reading is -398.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is 0.61 and Total Capital is -1.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8337 points at the first support level, and at 0.8174 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8726, and for the 2nd resistance point, it is at 0.8952.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Seres Therapeutics Inc [NASDAQ:MCRB] is 1.12. On the other hand, the Quick Ratio is 1.12, and the Cash Ratio is 1.03. Considering the valuation of this stock, the price to sales ratio is 2418.75, the price to book ratio is 6.05.
Transactions by insiders
Recent insider trading involved DesRosier Thomas, Chief Legal Officer and EVP, that happened on Nov 18 ’24 when 878.0 shares were sold., von Moltke Lisa completed a deal on Nov 18 ’24 to sell 977.0 shares. Meanwhile, CEO and President Shaff Eric D. sold 2505.0 shares on Nov 18 ’24.
